SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: eico20 who wrote (1840)4/11/2016 2:35:10 PM
From: mokelumne river  Read Replies (1) of 2026
 
Eman/MI, every time I think about profitability based on Vitaros, I come up with the following:

Annual operating costs, assuming a 30% reduction, are very roughly in the range of between $15M to $20M.

Vitaros royalties are roughly in the range of between $2 and $2.50 per unit.

To be profitable over those ranges, annual sales would have to be between 7.5M and 10M using $2 per unit royalty and 6M and 8M using $2.50 per unit. So, to fully offset annual operating costs, we are talking about sales in the neighborhood of say 2M units per quarter if my math holds or four times what they are on track to be selling in the near term.

Bottom line: The company's licensees have about 5 - 6 quarters to increase sales by four fold to achieve profitability in 2H17.

Is that doable?

Sandoz needs to get off its butt as all the countries approved for commercialization need to be selling...with no additional bumps in the road.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News